Tazarotene betamethasone cream, a new drug of psoriasis Class 1.5 of Huabang pharmaceutical, will be on the market soon

According to the website of the State Food and Drug Administration (CFDA), the state of 1.5 skin disease drug tazarotene betamethasone cream of Huabang pharmaceutical was changed to "under approval", which means that the drug has passed the technical review and production site inspection, entered the final approval stage, and is expected to get the production approval document in about three months Tazarotene betamethasone cream is a compound preparation of tazarotene and betamethasone, which is mainly used for the treatment of psoriasis It is developed by Huabang pharmaceutical, and has not been declared by other manufacturers After being approved, it will become an exclusive product The market is expected to reach 100-200 million It is worth mentioning that the tazarotene betamethasone cream of Huabang Yingtai has been listed as one of the 76 major special varieties published by CDE As early as 2012, the product was included in the list of 100 key products of Chongqing pharmaceutical industry, with a total investment of 8 billion yuan Huabang pharmaceutical has been positioned in the field of Dermatology since its establishment It has concentrated on the development of Dermatology prescription drug market for many years At present, the company has a self-supporting sales team of 700-800 people, including more than 600 hospital sales, which has a congenital advantage in sales channels According to the 2014 performance express data, the company achieved a total operating revenue of 4.921 billion yuan in 2014, a year-on-year increase of 10.3%; and a net profit of 426 million yuan attributable to shareholders of the listed company, a year-on-year increase of 41.0%.